Bromo-DragonFLY
| Bromo-DragonFLY | |
|---|---|
| Chemical name | Bromo-benzodifuranyl-isopropylamine or (1-(8-bromobenzo[1,2-b;4,5-b']difuran- 4-yl)-2-aminopropane |
| Chemical formula | C13H12BrNO2 |
| Molecular mass | 294.14 g/mol |
| Melting point | decomposes at 240 °C (hydrochloride) |
| CAS number | - |
| SMILES | N[C@H](C)CC1=C(OC=C2)C2= C(Br)C3=C1C=CO3 (R-isomer) |
|
WikiDoc Resources for Bromo-DragonFLY |
|
Articles |
|---|
|
Most recent articles on Bromo-DragonFLY Most cited articles on Bromo-DragonFLY |
|
Media |
|
Powerpoint slides on Bromo-DragonFLY |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Bromo-DragonFLY at Clinical Trials.gov Trial results on Bromo-DragonFLY Clinical Trials on Bromo-DragonFLY at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Bromo-DragonFLY NICE Guidance on Bromo-DragonFLY
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Bromo-DragonFLY Discussion groups on Bromo-DragonFLY Patient Handouts on Bromo-DragonFLY Directions to Hospitals Treating Bromo-DragonFLY Risk calculators and risk factors for Bromo-DragonFLY
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Bromo-DragonFLY |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Bromo-DragonFLY, also known as ABDF, is a psychedelic hallucinogenic drug somewhat related to the phenethylamine family. Bromo-DragonFLY is considered an extremely potent hallucinogen, only slightly less potent than LSD with a normal dose in the region of 200μg to 800μg, and it has an extremely long duration of action. It is not illegal anywhere in the world at this time (except in Sweden, where it is classified as an narcotic) although it may be considered a controlled substance analogue under US and Australian drug laws. Bromo-DragonFLY has a stereocenter and R-(-)-bromo-DragonFLY is the more active stereoisomer.
Pharmacology
The hallucinogenic effect of bromo-DragonFLY is mediated by its agonist activity at the 5-HT2A serotonin receptor. Bromo-DragonFLY also has a high binding affinity for the 5-HT2B and 5-HT2C serotonin receptor. User reports of the effects of bromo-DragonFLY suggest that while the effects are very long lasting, they tend to be somewhat milder than those of traditional hallucinogens such as LSD, suggesting that while bromo-DragonFLY is a full agonist at the 5HT2A receptor, it may not be activating the intracellular signalling pathways following receptor binding as effectively as LSD.
History
Bromo-DragonFLY was first synthesized by Matthew A. Parker in the laboratory of David E. Nichols in 1998.
Deaths
Bromo-DragonFLY can sometimes be found on "blotters" (small bits of paper containing the substance) reminiscent of the most commonly found form of LSD, thus making it difficult to identify which substance it is carrying. Erowid reports two news stories, one in Sweden and one in Norway, about deaths possibly involved with bromo-dragonFLY. Erowid Bromo-Dragonfly vault
See also
References
- 'A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor' by M. A. Parker, D. Marona-Lewicka, V. L. Lucaites, D. L. Nelson, and D. E. Nichols in J. Med. Chem. 41(26): 5148-5149 (1998) DOI: 10.1021/jm9803525
- 'Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT2A/2C receptor agonists' by J. J. Chambers, D. M. Kurrasch-Orbaugh, M. A. Parker, and D. E. Nichols in J. Med. Chem. 44(6): 1003-1010 (2001) DOI: 10.1021/jm000491y
External links
Template:Hallucinogenic phenethylamines